Topics › Companies & Deals
Companies & Deals: Biotech News Without the Hype
Acquisitions, partnerships and trial readouts in gene editing and heart biotech, explained from primary sources. No investment advice.
Get the newsletter →Deals decide which science gets funded and which treatments get the resources to reach late-stage trials. We cover acquisitions, partnerships and trial readouts in gene editing and cardiovascular biotech, with the primary announcement linked.
Quick answer: Deal news matters to readers because money and ownership shape which experimental treatments move forward. Example: Eli Lilly agreed on June 17, 2025 to acquire Verve Therapeutics, a gene editing company focused on cholesterol, and completed the deal on July 25, 2025.
How we cover deals
- Link the company or regulator announcement.
- State the stage of the science (preclinical, Phase 1, approved).
- Separate the price tag from the evidence.
- No stock tips or investment advice.
Example: Lilly and Verve
Lilly said the agreement valued Verve at about $1.0 billion up front, with up to about $1.3 billion including a contingent value right tied to a future Phase 3 milestone. Verve's lead program, VERVE-102, is an investigational base editing treatment targeting PCSK9.
Latest Companies and Deals stories
First stories in this section are being written. Get notified when the newsletter opens.
Frequently asked questions
Does Darwi give investment advice?
No. We explain the science and the deal terms from primary sources. Nothing on Darwi is investment advice.
Where do deal facts come from?
From company press releases, SEC filings and regulator notices, linked in each story.
Sources
Related topics
Darwi is for education only and is not medical advice. Talk with a qualified clinician about your health. Medical disclaimer.